Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed) | RFA DE 19 008

Frequently Asked Questions (FAQs)

What is the title of this NIH funding opportunity?

The opportunity is titled "Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)."

What is the main purpose of this FOA?

This NIH exploratory/developmental announcement is designed to push intraoral biodevices closer to real-world clinical use by funding early-stage, high-impact engineering work that removes key technical roadblocks. The emphasis is on transformative or substantially optimized approaches that improve how oral biodevices are built, integrated, validated, and positioned for translation toward patient care.

What kinds of projects fit best (high level)?

Projects that create enabling technologies, components, and proof-of-concept prototypes for devices that operate inside the mouth. Competitive concepts are expected to go beyond incremental tweaks and instead meaningfully improve feasibility, reliability, safety, durability, biocompatibility, and clinically relevant function in the oral environment.

What exactly is meant by "oral biodevices" in this announcement?

Based on the description, oral biodevices are integrated intraoral platforms that may combine electronic, physical, and biological systems to perform clinically relevant sensing (for detection/diagnosis) and/or clinically relevant actions (for treatment), while operating within the mechanically demanding and biologically complex environment of the mouth.

What makes the oral environment technically challenging for devices?

The FOA highlights that the mouth is both mechanically demanding and biologically complex. The device must maintain performance and durability while also meeting biocompatibility and safety needs, all while reliably operating in an intraoral setting and producing clinically meaningful outputs.

What types of applications does NIH want these devices to support?

The intended applications include detection, diagnosis, and treatment of oral diseases. The FOA also extends interest to systemic health conditions where oral measurements can provide useful information.

How does this FOA connect to precision medicine?

Precision medicine is emphasized as a goal area, meaning devices and sensors that can support more individualized assessment and care. This can include measuring biomarkers or capturing patient-specific measurements that are relevant to individualized decision-making.

What does the FOA mean by measuring "patient functional status" and "clinical outcome assessment"?

The FOA calls attention to devices that quantify meaningful patient-centered metrics, not just raw sensor signals. In other words, the goal is to generate measurements that can be interpreted as clinically relevant outcomes or functional status indicators.

What outputs or deliverables are expected from funded projects?

Expected outputs include tangible enabling products such as proof-of-concept prototype oral biodevices, specialized biosensors, and core supporting technologies that can be reused or adapted across multiple device concepts.

Is theoretical modeling alone sufficient?

The FOA is framed around accelerating development and encourages work that demonstrates feasibility and de-risks a pathway toward later-stage development. That implies the program is looking for more than theory alone, with an emphasis on prototype creation, bench testing, validation in relevant non-clinical settings, and engineering optimization.

Are clinical trials allowed under this R21?

No. The FOA explicitly states "Clinical Trial Not Allowed," meaning supported work should remain preclinical and developmental rather than conducting formal clinical trials in human participants as defined by NIH policy.

What kinds of testing and validation activities are appropriate if clinical trials are not allowed?

The description indicates appropriate activities include prototype creation, bench testing, validation in relevant non-clinical settings, and engineering optimization aimed at feasibility and de-risking later translation.

What types of expertise or team structure does NIH encourage?

The FOA strongly encourages interdisciplinary collaboration, reflecting that oral biodevices sit at the intersection of multiple fields. It calls out collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry.

Are academia-industry partnerships welcomed?

Yes. The FOA specifically welcomes partnerships between academia and industry, signaling interest in teams that can connect technical development with translational needs such as manufacturability, usability, and safety considerations for eventual deployment.

What is the funding mechanism?

The announcement uses the NIH R21 exploratory/developmental mechanism.

What is the maximum award amount mentioned?

The listed award ceiling is $200,000.

What is the Funding Opportunity Number?

The Funding Opportunity Number is RFA-DE-19-008.

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 93.121.

What were the key dates provided in the announcement summary?

The creation date is November 15, 2018, and the original closing date is March 19, 2019.

Who is eligible to apply (in general terms)?

Eligibility is broad for U.S.-based applicants and includes a wide range of organization types spanning government entities, educational institutions, nonprofits, and for-profit organizations, including small businesses (as listed in the announcement).

Which government entities are eligible?

Eligible government-related applicants include state governments, county governments, local governments, independent school districts, special district governments, federally recognized tribal governments, tribal organizations not federally recognized, and public housing authorities/Indian housing authorities.

Which education and research organizations are eligible?

Public and private institutions of higher education are eligible, along with the institutional categories specifically highlighted in the announcement (for example, HBCUs, Hispanic-serving institutions, AANAPISIs, Tribal Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and organizations in U.S. territories or possessions).

Are nonprofits eligible?

Yes. Nonprofits with or without 501(c)(3) status are listed as eligible.

Are for-profit organizations eligible?

Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible.

Are faith-based or community-based organizations eligible?

The FOA explicitly notes interest in eligibility from faith-based or community-based organizations among the institutional categories it calls out.

Can non-U.S. organizations apply?

No. Non-U.S. entities and non-U.S. components of U.S. organizations are not eligible to apply, based on the eligibility information provided.

Are any foreign activities allowed at all?

Yes, foreign components (as defined by NIH policy) are allowed. In practical terms, the summary indicates a U.S. applicant may include certain well-justified foreign elements within the project while remaining a U.S.-led application.

What kinds of solutions does NIH seem to prioritize technically?

The FOA prioritizes integrated systems engineering solutions that allow devices to reliably function inside the mouth while maintaining performance, durability, biocompatibility, and safety, and while generating clinically relevant data or delivering clinically relevant actions.

What is meant by "enabling technologies" in this context?

Within the FOA description, enabling technologies include core supporting technologies, specialized biosensors, and reusable building blocks that can be adapted across multiple oral biodevice concepts, helping accelerate development across the field rather than supporting only a single narrow device iteration.

What is the overall theme reviewers are likely to look for?

Based on the FOA description, the theme is acceleration toward practical translation: interdisciplinary, prototype-oriented engineering that addresses real intraoral constraints, produces tangible outputs, and lays groundwork for the next stage of development without conducting clinical trials.